Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jan;275(1):245-261.
doi: 10.1111/imr.12514.

Complex immune correlates of protection in HIV-1 vaccine efficacy trials

Georgia D Tomaras  1 , Stanley A Plotkin  2   3
Affiliations
Review

Complex immune correlates of protection in HIV-1 vaccine efficacy trials

Georgia D Tomaras et al. Immunol Rev. 2017 Jan.

Abstract

Development of an efficacious HIV-1 vaccine is a major priority for improving human health worldwide. Vaccine-mediated protection against human pathogens can be achieved through elicitation of protective innate, humoral, and cellular responses. Identification of specific immune responses responsible for pathogen protection enables vaccine development and provides insights into host defenses against pathogens and the immunological mechanisms that most effectively fight infection. Defining immunological correlates of transmission risk in preclinical and clinical HIV-1 vaccine trials has moved the HIV-1 vaccine development field forward and directed new candidate vaccine development. Immune correlate studies are providing novel hypotheses about immunological mechanisms that may be responsible for preventing HIV-1 acquisition. Recent results from HIV-1 immune correlates work has demonstrated that there are multiple types of immune responses that together, comprise an immune correlate-thus implicating polyfunctional immune control of HIV-1 transmission. An in depth understanding of these complex immunological mechanisms of protection against HIV-1 will accelerate the development of an efficacious HIV-1 vaccine.

Keywords: HIV; antibodies; cellular; complex immune correlate; correlate of decreased HIV-1 risk; correlates of protection; humoral; immunity; sieve analysis; vaccination.

PubMed Disclaimer

Similar articles

  • Advances in HIV-1 Vaccine Development.
    Gao Y, McKay PF, Mann JFS. Gao Y, et al. Viruses. 2018 Apr 1;10(4):167. doi: 10.3390/v10040167. Viruses. 2018. PMID: 29614779 Free PMC article. Review.
  • New concepts in HIV-1 vaccine development.
    Stephenson KE, D'Couto HT, Barouch DH. Stephenson KE, et al. Curr Opin Immunol. 2016 Aug;41:39-46. doi: 10.1016/j.coi.2016.05.011. Epub 2016 Jun 3. Curr Opin Immunol. 2016. PMID: 27268856 Free PMC article. Review.
  • Prospects for a globally effective HIV-1 vaccine.
    Excler JL, Robb ML, Kim JH. Excler JL, et al. Vaccine. 2015 Nov 27;33 Suppl 4:D4-12. doi: 10.1016/j.vaccine.2015.03.059. Epub 2015 Jun 20. Vaccine. 2015. PMID: 26100921 Review.
  • HIV-1 vaccines and adaptive trial designs.
    Corey L, Nabel GJ, Dieffenbach C, Gilbert P, Haynes BF, Johnston M, Kublin J, Lane HC, Pantaleo G, Picker LJ, Fauci AS. Corey L, et al. Sci Transl Med. 2011 Apr 20;3(79):79ps13. doi: 10.1126/scitranslmed.3001863. Sci Transl Med. 2011. PMID: 21508308 Free PMC article.
  • Challenges in the development of an HIV-1 vaccine.
    Barouch DH. Barouch DH. Nature. 2008 Oct 2;455(7213):613-9. doi: 10.1038/nature07352. Nature. 2008. PMID: 18833271 Free PMC article. Review.
See all similar articles

Cited by

See all "Cited by" articles

References

    1. Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol. 2010;17(7):1055–1065. - PMC - PubMed
    1. Plotkin SA, Gilbert PB. Nomenclature for immune correlates of protection after vaccination. Clin Infect Dis. 2012;54(11):1615–1617. - PMC - PubMed
    1. Plotkin SA. Complex correlates of protection after vaccination. Clin Infect Dis. 2013;56(10):1458–1465. - PubMed
    1. Plotkin SA. Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis. 2008;47(3):401–409. - PubMed
    1. Iwasaki A. Exploiting Mucosal Immunity for Antiviral Vaccines. Annu Rev Immunol. 2016;34:575–608. - PubMed

Publication types

-